Spineart's BAGUERA® C Cervical Disc Prosthesis Meets Non-Inferiority Thresholds in Both 1-Level and 2-Level IDE Studies
核心洞察
Spineart (搜索) announced that interim analyses of both its 1-level and 2-level BAGUERA® C (搜索) IDE studies have met thresholds for non-inferiority claims against the control device Mobi-C® (搜索) for treating symptomatic cervical disc disease (搜索).
The company has agreed with the FDA on a timeline for a combined Premarket Approval (PMA) submission for both indications, with completion scheduled for August 2025, potentially enabling earlier approval than initially anticipated.
The clinical trials enrolled nearly 600 patients across 30 U.S. sites, representing a significant milestone in Spineart (搜索)'s mission to provide innovative solutions for cervical spine treatment.
Spineart (搜索) announced today that its cervical disc prosthesis BAGUERA® C (搜索) has met non-inferiority thresholds in interim analyses of both its 1-level and 2-level IDE clinical studies, marking a significant advancement toward U.S. market approval.
The Geneva-based spine surgery innovation company completed the planned interim analysis for its 2-level BAGUERA® C (搜索) IDE study in April 2025, following positive interim results from its 1-level study announced in March. Both analyses demonstrated that the BAGUERA® C device met the threshold for non-inferiority claims against the study control, Mobi-C® (搜索) cervical disc.
"The interim analysis data from our 2-level study is a significant milestone for Spineart (搜索), coming less than a month after the promising interim results of our 1-level study," said Jerome Trividic, Chief Executive Officer at Spineart. "These findings bring us closer to providing patients with a highly effective solution for treating symptomatic cervical disease at multiple levels, potentially improving their quality of life."
Clinical Trial Design and Patient Enrollment
The BAGUERA® C (搜索) IDE trials are prospective, multi-center, randomized clinical studies evaluating the safety and efficacy of the device compared with Mobi-C® (搜索) in treating symptomatic cervical disc disease (搜索). The 1-level study enrolled 285 patients across 25 U.S. sites, while the combined 1-level and 2-level studies included nearly 600 patients at 30 sites throughout the United States.
Both studies are designed to assess the device's performance in maintaining or restoring segmental motion and disc height in the cervical spine following single- or two-level discectomy for symptomatic cervical disc disease (搜索).
Regulatory Pathway and Timeline
Following these positive interim results, Spineart (搜索) has agreed with the FDA to submit data from both IDE studies under a single Premarket Approval (PMA) application. The company plans to submit the PMA in three separate modules, with completion scheduled for the end of August 2025.
This regulatory strategy could potentially accelerate the approval timeline, bringing the innovative cervical disc prosthesis to U.S. patients sooner than originally anticipated. The combined submission approach represents an efficient regulatory pathway that may benefit both the company and patients awaiting new treatment options.
BAGUERA® C Technology and Design
The BAGUERA® C (搜索) cervical disc prosthesis is designed to maintain the natural behavior of a functional spinal unit. Its innovative design enables the nucleus to move in all six degrees of freedom, with independent angular rotations (flexion-extension, lateral bending, and axial rotation) along with independent translational motions.
This biomechanical approach aims to closely replicate natural cervical spine movement while maintaining disc height and segmental motion following discectomy procedures. The device remains investigational in the United States, though Spineart (搜索) has established itself as a growing presence in spine surgery innovation globally.
Company Background and Market Position
Spineart (搜索) has positioned itself as a fast-growing company in spine surgery innovation, dedicated to accelerating the adoption of cutting-edge technologies for surgeons and hospitals worldwide. The company's commitment to quality, innovation, and simplicity has been recognized with the "Prix de l'Economie Genevoise 2022" for its contributions to technological and scientific innovations, commercial activities, job creation, and ESG principles.
The potential U.S. approval of BAGUERA® C (搜索) would represent a significant expansion opportunity for Spineart (搜索) in the competitive cervical disc replacement market, currently dominated by established devices like Mobi-C® (搜索).
Clinical Implications and Future Outlook
If approved, the BAGUERA® C (搜索) device would provide surgeons and patients with an additional option for treating symptomatic cervical disc disease (搜索), potentially offering advantages in terms of motion preservation and functional outcomes.
"We are committed to advancing spinal health and working with the FDA to bring BAGUERA® C (搜索) to patients in the United States," added Trividic, highlighting the company's focus on expanding access to innovative spine technologies.
The completion of the full clinical studies and subsequent FDA review will determine whether BAGUERA® C (搜索) receives final approval for both 1-level and 2-level indications in the U.S. market, potentially offering new treatment options for patients suffering from degenerative cervical disc disease (搜索).